首页> 外文期刊>Neuropsychiatric Disease and Treatment >Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
【24h】

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)

机译:路易氏体痴呆患者的人口统计学,诊断和药物治疗以及痴呆患者的帕金森氏病:来自瑞典痴呆症质量注册机构(SveDem)的数据

获取原文
       

摘要

Introduction: Whether dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) should be considered as one entity or two distinct conditions is a matter of controversy. The aim of this study was to compare the characteristics of DLB and PDD patients using data from the Swedish Dementia Quality Registry (SveDem). Methods: SveDem is a national Web-based quality registry initiated to improve the quality of diagnostic workup, treatment, and care of patients with dementia across Sweden. Patients with newly diagnosed dementia of various types were registered in SveDem during the years 2007–2011. The current cross-sectional report is based on DLB (n = 487) and PDD (n = 297) patients. Demographic characteristics, diagnostic workup, Mini-Mental State Examination (MMSE) score, and medications were compared between DLB and PDD groups. Results: No gender differences were observed between the two study groups (P = 0.706). PDD patients were significantly younger than DLB patients at the time of diagnosis (74.8 versus 76.8 years, respectively; P < 0.001). A significantly higher prevalence of patients with MMSE score #24 were found in the PDD group (75.2% versus 67.6%; P = 0.030). The mean number of performed diagnostic modalities was significantly higher in the DLB group (4.9 ± 1.7) than in the PDD group (4.1 ± 1.6; P< 0.001). DLB patients were more likely than PDD patients to be treated with cholinesterase inhibitors (odds ratio = 2.5, 95% confidence interval = 1.8–3.5), whereas the use of memantine, antidepressants, and antipsychotics did not differ between the groups. Conclusion: This study demonstrates several differences in the dementia work-up between DLB and PDD. The onset of dementia was significantly earlier in PDD, while treatment with cholinesterase inhibitors was more common in DLB patients. Severe cognitive impairment (MMSE score ≤24) was more frequent in the PDD group, whereas more diagnostic tests were used to confirm a DLB diagnosis. Some similarities also were found, such as gender distribution and use of memantine, antidepressants, and antipsychotics drugs. Further follow-up cost-effectiveness studies are needed to provide more evidence for workup and treatment guidelines of DLB and PDD.
机译:简介:是否应将路易体痴呆症(DLB)和帕金森氏病伴痴呆症(PDD)视为一个整体还是两个不同的状况,这是一个有争议的问题。这项研究的目的是使用瑞典痴呆症质量注册中心(SveDem)的数据比较DLB和PDD患者的特征。方法:SveDem是一个基于国家Web的国家质量注册中心,旨在提高瑞典各地痴呆症患者的诊断检查,治疗和护理质量。在2007-2011年期间,在SveDem中注册了新诊断为各种类型的痴呆症的患者。当前的横断面报告基于DLB(n = 487)和PDD(n = 297)患者。在DLB组和PDD组之间比较了人口统计学特征,诊断检查,小精神状态检查(MMSE)得分和药物治疗。结果:两个研究组之间未观察到性别差异(P = 0.706)。在诊断时,PDD患者明显比DLB患者年轻(分别为74.8岁和76.8岁; P <0.001)。在PDD组中,MMSE评分为#24的患者患病率明显更高(75.2%对67.6%; P = 0.030)。 DLB组(4.9±1.7)的平均诊断方法数量明显高于PDD组(4.1±1.6; P <0.001)。 DPD患者比PDD患者更可能接受胆碱酯酶抑制剂治疗(几率= 2.5,95%置信区间= 1.8-3.5),而美金刚,抗抑郁药和抗精神病药的使用在两组之间没有差异。结论:这项研究证明了DLB和PDD在痴呆症检查方面存在一些差异。在PDD中,痴呆症的发作明显较早,而在DLB患者中,胆碱酯酶抑制剂的治疗更为常见。在PDD组中,严重的认知障碍(MMSE评分≤24)更为常见,而更多的诊断测试被用来确认DLB的诊断。还发现了一些相似之处,例如性别分布和美金刚,抗抑郁药和抗精神病药的使用。需要进一步的随访成本-效果研究,以为DLB和PDD的检查和治疗指南提供更多证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号